ABCA4 and Stargardt disease: To overcome this constraint, several alternative platforms including dual-AAV systems, RNA-based therapies, lentiviral vectors, and emerging non-viral technologies are under active investigation to enable efficient delivery of full-length ABCA4 and expand therapeutic options for patients with Stargardt disease.